Skip to main content
Top
Published in: Annals of Surgical Oncology 8/2022

21-03-2022 | NSCLC | ASO Author Reflections

ASO Author Reflection: Primary Tumor Resection for Stage IV Lung Cancer after Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

Authors: Pei-Hsing Chen, M.D., Shuenn-Wen Kuo, M.D., Ph.D., Jin-Shing Chen, M.D., Ph.D.

Published in: Annals of Surgical Oncology | Issue 8/2022

Login to get access

Excerpt

Although administration of epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs) results in a longer progression free survival (PFS) than chemotherapy, progression inevitably occurs after 1–2 years. Previous studies1 have shown that most progression occurs at the primary site; thus, radiotherapy could improve the time to progression in a significant number of patients. Local consolidative therapy, which includes surgery and radiotherapy, was administered to selected patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC) and proved to be effective.2 However, the data were mainly evaluated for radiotherapy, and patients who underwent surgery accounted for < 10% of the population. Some recent studies3,4 have investigated the role of thoracic surgery in metastatic NSCLC; however, inconclusive results were obtained. Thus, data on primary tumor resection after EGFR–TKI treatment without progression in patients with pure stage IV EGFR-mutant NSCLC are limited. …
Literature
1.
go back to reference Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis Acta Oncol. 2009;48:578–83.PubMed Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis Acta Oncol. 2009;48:578–83.PubMed
2.
go back to reference Elamin YY, Gomez DR, Antonoff MB, et al. Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2019;20:43–7.CrossRef Elamin YY, Gomez DR, Antonoff MB, et al. Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2019;20:43–7.CrossRef
3.
go back to reference Fu F, Wen Z, Gao Z, et al. Primary tumor resection improves survival for EGFR-TKI-treated patients with occult M1a lung adenocarcinoma. Front Oncol. 2021;11:622723–622723.CrossRef Fu F, Wen Z, Gao Z, et al. Primary tumor resection improves survival for EGFR-TKI-treated patients with occult M1a lung adenocarcinoma. Front Oncol. 2021;11:622723–622723.CrossRef
4.
go back to reference Tseng JS, Hsu KH, Zheng ZR, et al. Primary tumor resection is associated with a better outcome among advanced EGFR-mutant lung adenocarcinoma patients receiving EGFR-TKI treatment. Oncology. 2020;99:32–40.CrossRef Tseng JS, Hsu KH, Zheng ZR, et al. Primary tumor resection is associated with a better outcome among advanced EGFR-mutant lung adenocarcinoma patients receiving EGFR-TKI treatment. Oncology. 2020;99:32–40.CrossRef
Metadata
Title
ASO Author Reflection: Primary Tumor Resection for Stage IV Lung Cancer after Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
Authors
Pei-Hsing Chen, M.D.
Shuenn-Wen Kuo, M.D., Ph.D.
Jin-Shing Chen, M.D., Ph.D.
Publication date
21-03-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 8/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-11487-3

Other articles of this Issue 8/2022

Annals of Surgical Oncology 8/2022 Go to the issue
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare